Research supports use of NPS Pharmaceuticals’ osteoporosis drug

A new drug application for Preos is currently under review by the FDA. The European Medicines Agency is also reviewing the market authorization application for Preotact, the European equivalent to Preos, which will be marketed in Europe by Nycomed, an NPS partner.

“New analyses and studies are giving us greater insight into how Preos reduces vertebral fracture risk in postmenopausal women with osteoporosis,” said Dr David Dempster, professor of Clinical Pathology at Columbia University and director of the Helen Hayes Hospital Regional Bone Center in New York. “With these studies, we’re seeing more than just increases in bone mass, we’re seeing changes indicative of improved skeletal architecture that more closely resembles strong, healthy bone.”